Scienza e Tecnologia
Immuno-oncology Cell Therapy Market worth $34.69 Billion by 2030 - Exclusive Report by InsightAce Analytic
The introduction of new immunotherapies for cancer treatment has drastically transformed the landscape of the oncology industry. Immunotherapy is a relatively recent topic of cancer treatment. Immunotherapy aims to use the immune system's ability to recognize, target, and kill malignant cells. Immuno-oncology is a biological treatment that boosts the body's immune system to stop cancer growth. The oncology market today could be quickly superseded by next-generation therapies in the upcoming forecast period. Their ongoing clinical trials and recent FDA approvals emphasize their potential as effective first-line or follow-up cancer medicines. One of the most significant developments in cancer since the introduction of chemotherapy is the approval of CAR-T cell therapy products. The current clinical development focuses on identifying new indications for T cell therapy, developing safer T cell therapy platforms, and manufacturing T cell therapy more efficiently. Furthermore, COVID-19 Pandemic is significantly increasing the need for immuno-oncology cell therapies, and hence, in future, there will be a high requirement of cell therapies, which will ultimately result in immuno-oncology cell therapy market growth.
The Immuno-oncology Cell Therapy market growth is attributed to numerous factors including fast adoption of cancer immunotherapies over other conventional cancer treatments, development of bioinformatics tools, high prevalence of cancer worldwide, and increased demand for personalized medicine. According to the American Cancer Society, In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States . The rising number of research and funding activities in the immune-oncology and robust focus on research activities from government health institutions and pharma giants in Immuno-oncology therapy development is expected to drive the market growth over the forecast period. Furthermore, the use of various bioinformatics tools reduces the cost and time of the drug development process, enabling pharmaceutical companies to monitor and evaluate their products more efficiently and rapidly. Thus, bioinformatics and different software tools increase the interest of researchers to innovate novel cancer therapies, thereby increasing the adoption of the cancer immunotherapy market.
However, the high cost of immuno-oncology therapies, stringent regulatory requirements for biomarkers, and poor reimbursement policies are expected to hamper the growth of market during the forecast period. Geographically, North America is expected to dominate the market over the forecast period, owing to high healthcare expenditure and awareness among people. European region also holds a significant market share for the immuno-oncology cell therapies market. It is expected that the support provided by government bodies for research & development and increased clinical trial programs in healthcare will drive the market in the European region. Asia Pacific region is expected to witness the fastest growth during the forecast period (2021-2030) due to the high prevalence of cancer, increasing use of bioinformatics tools & data for drug designing, and rising government funding for healthcare sector. Significantly, China , India , and Japan are the major countries in this market.
The immuno-oncology cell therapy market is fragmented with the presence of many players with therapeutic products in clinical trials, which are expected to get approval in the upcoming forecast period. Most of the leading players use various strategies such as new product launches in developed countries, partnerships, expansions, agreements, mergers, and acquisitions to increase their value in this market. In January 2021 , Novartis ( Switzerland ) collaborated with BeiGene, Ltd. to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China . This agreement is expected to accelerate the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages
The global immuno-oncology cell therapy market covers prominent players like Agios Pharmaceutical, Atara Biotherapeutics, Novartis, Juno Therapeutics, Allogene Therapeutics, Shenzhen BinDeBio Ltd., Kite Pharma, Autolus Limited, China Immunotech Co., Ltd., Bellicum Pharmaceuticals, bluebird bio, CARsgen Therapeutics, Cell Design Labs, Calibr, Carina Biotech, Editas Medicine, Celgene Corporation, Cellectis, Cell Medica, Amgen, Celularity, Celyad, Fortress Bio, Fate Therapeutics, Gilead Sciences, JW Therapeutics, Mustang Bio, Ziopharm, Sorrento Therapeutics, Inc., Medigene, Medisix Therapeutics, Precision Biosciences, Lion TCR, Nanjing Legend Biotech, Posedia Therapeutics, Zelluna Immunotherapy, and others prominent players.
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on
Europe Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
North America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
Asia Pacific Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
Latin America Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
Middle East & Africa Immuno-oncology cell therapies market Revenue (US$ Million) by Country, 2022 to 2030
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact Us:
Priyanka Tilekar
InsightAce Analytic Pvt. Ltd.
Asia : +91 79 72967118
Tel : +1 551 226 6109
Email: info@insightaceanalytic.com
Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg